Benitec Biopharma Inc. (BNTC) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Benitec Biopharma Inc. (NASDAQ: BNTC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $8.74 (-1.02% 1D, market cap $304.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BNTC ranks #796 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BNTC carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IRD (Opus Genetics Inc.) holds a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $305.3M) and VOGX (Vogenx Inc) posts a D grade (45/100 RQD, P/E N/A, ROIC —, cap $300.8M). Among the 5-stock peer group, BNTC leads on earnings multiple (N/A) while BNTC leads on capital efficiency (-35.0% ROIC).
Per BNTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001808898), Benitec Biopharma Inc. generated $0 in revenue, -$37.9M in net income, and -$23.6M in free cash flow against $190.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While BNTC currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($10.22) and Max Pain ($9.18) forces dealer call-delta covering toward $17.13.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Benitec Biopharma Inc. (BNTC) slipped -1.02% to $8.74, trading at 10% of its 52-week range ($7.89 – $16.31). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Benitec Biopharma Inc. (BNTC) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Benitec Biopharma Inc. (BNTC) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Benitec Biopharma Inc. (BNTC) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Benitec Biopharma Inc. (BNTC) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Benitec Biopharma Inc. (BNTC) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Benitec Biopharma Inc. (BNTC) market action, institutional positioning, and fundamental catalysts.
Kalkine Media report covering Benitec Biopharma Inc. (BNTC) market action, institutional positioning, and fundamental catalysts.
- Both low dose and high dose BB-301 continue to drive robust improvements in swallowing function for dysphagic Patients with Oculopharyngeal Muscular Dystrophy (OPMD) - 100% of Patients treated with BB-301 across both d
Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BNTC today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BNTC. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Benitec Biopharma Inc. (BNTC) ranks #796 by composite RQD confidence (30/100, grade E) and #515 by equity capitalization ($304.9M). Within this direct 5-issuer industry benchmark cohort, BNTC leads on earnings valuation at N/A trailing P/E, while BNTC leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. VOGX currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with BNTC at 30/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BNTC
ACTIVE
Benitec Biopharma Inc. | E | 30/100 | — | — | -35.0% | -1.02% | $304.9M | Benchmark Subject |
| IRD Opus Genetics Inc. | E | 23/100 | — | — | -35.0% | +0.55% | $305.3M | /ird-vs-bntc → |
| VOGX Vogenx Inc | D | 45/100 | — | — | — | +1.66% | $300.8M | /vogx-vs-bntc → |
| PRLD Prelude Therapeutics Incorporated | E | 33/100 | — | — | -35.0% | -5.37% | $309.6M | /prld-vs-bntc → |
| ENTA Enanta Pharmaceuticals Inc. | E | 20/100 | — | — | -35.0% | -3.95% | $311.9M | /enta-vs-bntc → |
In its most recent audited fiscal period (FY2025, filed 2025-06-30), Benitec Biopharma Inc. (BNTC) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$37.9M, operating cash flow of -$23.6M, and free cash flow of -$23.6M (-20.5% YoY). On the balance sheet, BNTC closed FY2025 with $190.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-06-30 | $0 | -$37.9M | -$23.6M | -$23.6M | $190.7M | — |
| FY2024 (FY) | 2024-06-30 | $0 | -$21.8M | -$19.4M | -$19.6M | $79.1M | — |
| FY2023 (FY) | 2023-06-30 | $0 | -$19.6M | -$18.0M | -$18.0M | — | — |
As of 2026-11-03, Benitec Biopharma Inc. (NASDAQ: BNTC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $8.74 (-1.02% 1D, market cap $304.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BNTC ranks #796 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BNTC carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IRD (Opus Genetics Inc.) holds a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $305.3M) and VOGX (Vogenx Inc) posts a D grade (45/100 RQD, P/E N/A, ROIC —, cap $300.8M). Among the 5-stock peer group, BNTC leads on earnings multiple (N/A) while BNTC leads on capital efficiency (-35.0% ROIC).
Per BNTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001808898), Benitec Biopharma Inc. generated $0 in revenue, -$37.9M in net income, and -$23.6M in free cash flow against $190.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
BNTC last traded at $8.74 (-1.02% on volume of 135,494 shares), positioning the stock -14.48% below its 50-day simple moving average ($10.22) and -24.07% below its 200-day simple moving average ($11.51). Across its 52-week range of $7.89 to $16.31, BNTC sits at the 10.1% percentile with a 14-day RSI of 42.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($7.65 to $9.83).
Why BNTC Stock slipped -1.02% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, BNTC carries an RQD Score of 30 and a letter grade of E, with the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars score as follows: Fundamental Cash Engine 8/20 (ROIC -35%; FCF yield -7.66%), Whale 13F Flow 3/20, Insider Conviction 3/20, Macro Regime Fit 6/20 (Beta 1.0), and Forensic Balance Sheet 10/20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5). The weakest pillars are institutional flow and insider conviction, each at 3 out of 20. The cash engine score is also low, consistent with the negative ROIC and negative free cash flow yield. The forensic balance sheet pillar is the relative strength, with a Debt/Equity of 0.5 and an Altman Z of 2.5, though the Piotroski F of 2/9 signals weak financial health across the checks. For a prospective investor evaluating the stock today, the rating frames the current setup as high forensic risk. Upside would depend on the catalysts described below converting into sustained cash generation, which the source data does not yet show. This brief is analytical and educational, not personalized advice.
Benitec Biopharma Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the source profile, the company operates with a market capitalization of $0.3B. The source data does not specify its products, customers, or revenue model. Reported revenue in the SEC financials is $0.0M across all listed periods.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-41.8M | $-37.9M | N/A | $-23.6M | $188.8M | N/A |
| FY 2024 | $0.0M | $-22.5M | $-21.8M | N/A | $-19.6M | $78.3M | N/A |
| FY 2023 | $0.0M | $-19.1M | $-19.6M | N/A | $-18.0M | N/A | N/A |
Per the SEC financials, operating losses widened from $-19.1M in FY 2023 to $-41.8M in FY 2025, and net income losses followed a similar path. Gross, operating, and net margins are each reported as 0% in the market data. The Roarable RQD rating cites an ROIC of -35%, an Altman Z-Score of 2.5, and a Piotroski F-Score of 2/9. Reported cash rose to $188.8M in FY 2025 from $78.3M in FY 2024, while debt is listed as N/A in the source periods.
Per the recent news and catalysts feed, the most prominent items are: a regulatory update following a Type C meeting with the FDA regarding the BB-301 pivotal study (flagged YELLOW, MARKET WIRE); a TradingView report of a 12-month price target raised to $24.33, implying 171% upside (GREEN, CATALYST); Raymond James initiating coverage with an Outperform rating and a $14 price target (GREEN, CATALYST); and a Stock Titan report that every patient in the company's study responded to an experimental treatment for a disease that weakens swallowing (YELLOW, MARKET WIRE). A Benzinga initiation roundup also references BNTC (GREEN, CATALYST). Risk watch items: the feed includes only headline-level summaries and does not provide trial sample sizes, timelines, or regulatory terms. The butterfly supply-chain graph reports no supply-chain links and no proprietary signals.
Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. The source data therefore does not identify upstream suppliers, downstream customers, or sector correlations. Investors should watch whether the pivotal-study regulatory path, referenced in the news feed, affects the company's ability to fund operations given its reported negative free cash flow, since the source does not describe the company's funding structure beyond reported cash.
Real-time company headlines, analyst actions, and sector developments for Benitec Biopharma Inc. (BNTC) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Benitec Biopharma Inc. (BNTC) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Benitec Biopharma Inc. (BNTC) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Benitec Biopharma Inc. (BNTC) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Benitec Biopharma Inc. (BNTC) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Benitec Biopharma Inc. (BNTC) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Benitec Biopharma Inc. (BNTC) market action, institutional positioning, and fundamental catalysts.
Kalkine Media report covering Benitec Biopharma Inc. (BNTC) market action, institutional positioning, and fundamental catalysts.
- Both low dose and high dose BB-301 continue to drive robust improvements in swallowing function for dysphagic Patients with Oculopharyngeal Muscular Dystrophy (OPMD) - 100% of Patients treated with BB-301 across both d
Welcome to the BNTC (Benitec Biopharma Inc.) Roar Pit. Current RQD Composite is 30/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on BNTC, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Benitec Biopharma Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on BNTC, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $8.83 (52-wk range $7.89 - $16.68), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).